Combined inhibition of CDK4/6 and AKT is effective in Rb-intact triple-negative breast cancer of the luminal androgen receptor (LAR) subtype

被引：0
|
作者：
Kim, Gun Min
Lee, Kyung-min
Sudhan, Dhivya
Lin, Albert
Marin, Arnaldo
Chatterjee, Sumanta
Ye, Dan
Kandagatla, Vishal
Mendiratta, Saurabh
Hanker, Ariella
Arteaga, Carlos
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-PD3-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD3-07
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Combined inhibition of CDK4/6 and AKT is highly effective against the luminal androgen receptor (LAR) subtype of triple negative breast cancer
    Chica-Parrado, Maria Rosario
    Kim, Gun Min
    Uemoto, Yasuaki
    Napolitano, Fabiana
    Lin, Chang-Ching
    Ye, Dan
    Bikorimana, Emmanuel
    Fang, Yisheng
    Lee, Kyung-min
    Mendiratta, Saurabh
    Hanker, Ariella B.
    Arteaga, Carlos L.
    CANCER LETTERS, 2024, 604
  • [2] Combined inhibition of CDK4/6 and AKT is highly active against the luminal androgen receptor (LAR) subtype of triple negative breast cancer (TNBC)
    Chica-Parrado, Maria del Rosario
    Kin, Gun Min
    Lin, Chang-Ching
    Lee, Kyung-Min
    Napolitano, Fabiana
    Ye, Dan
    Bikorimana, Emmanuel
    Mendirata, Saurabh
    Hanker, Ariella
    Arteaga, Carlos L.
    CANCER RESEARCH, 2023, 83 (07)
  • [3] Combined inhibition of CDK4/6 and AKT is highly active against the luminal androgen receptor (LAR) subtype of triple negative breast cancer (TNBC)
    Chica-Parrado, Rosario
    Kim, Gun Min
    Uemoto, Yasuaki
    Ye, Dan
    Napolitano, Fabiana
    Lin, Chang-Ching
    Bikorimana, Emmanuel
    Lee, Kyung-Min
    Mendiratta, Saurabh
    Hanker, Ariella B.
    Arteaga, Carlos L.
    CANCER RESEARCH, 2024, 84 (06)
  • [4] Luminal androgen receptor (LAR) subtype of triple-negative breast cancer: molecular, morphological, and clinical features
    Vtorushin, Sergey
    Dulesova, Anastasia
    Krakhmal, Nadezhda
    JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B, 2022, 23 (08): : 617 - 624
  • [5] Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer
    Jennifer Y. Ge
    Shaokun Shu
    Mijung Kwon
    Bojana Jovanović
    Katherine Murphy
    Anushree Gulvady
    Anne Fassl
    Anne Trinh
    Yanan Kuang
    Grace A. Heavey
    Adrienne Luoma
    Cloud Paweletz
    Aaron R. Thorner
    Kai W. Wucherpfennig
    Jun Qi
    Myles Brown
    Piotr Sicinski
    Thomas O. McDonald
    David Pellman
    Franziska Michor
    Kornelia Polyak
    Nature Communications, 11
  • [6] Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer
    Ge, Jennifer Y.
    Shu, Shaokun
    Kwon, Mijung
    Jovanovi, Bojana
    Murphy, Katherine
    Gulvady, Anushree
    Fassl, Anne
    Trinh, Anne
    Kuang, Yanan
    Heavey, Grace A.
    Luoma, Adrienne
    Paweletz, Cloud
    Thorner, Aaron R.
    Wucherpfennig, Kai W.
    Qi, Jun
    Brown, Myles
    Sicinski, Piotr
    McDonald, Thomas O.
    Pellman, David
    Michor, Franziska
    Polyak, Kornelia
    NATURE COMMUNICATIONS, 2020, 11 (01)
  • [7] Investigating CDK4/6 inhibition in triple-negative breast cancer.
    Guo, Qiuchen
    Goreczny, Gregory J.
    Maynard, Adam
    Spasic, Milos
    McAllister, Sandra S.
    CANCER IMMUNOLOGY RESEARCH, 2020, 8 (03) : 40 - 40
  • [8] Association of luminal-androgen receptor (LAR) subtype with low HER2 in triple-negative breast cancer
    Ji, L. Min
    Ho, B. Seung
    Lee, S. E.
    Kook, Y.
    Moon, S.
    Kim, J.
    Kim, M. J.
    Bae, S. J.
    Jeong, J.
    Ahn, S. G.
    ANNALS OF ONCOLOGY, 2023, 34 : S303 - S303
  • [9] CDK4/6 inhibition in luminal breast cancer
    Gampenrieder S.P.
    Rinnerthaler G.
    Greil R.
    memo - Magazine of European Medical Oncology, 2016, 9 (2) : 76 - 81
  • [10] Investigating CDK4/6 inhibition in triple negative breast cancer
    Guo, Qiuchen
    Goreczny, Gregory J.
    Spasic, Milos
    Maynard, Adam
    McAllister, Sandra S.
    CANCER RESEARCH, 2021, 81 (04)
12345